Terms of use

Privacy

Privacy Settings

Imprint

Contact Us

Carolina Teichmann Cravo

Get in touch and send us an email.

Want to know more?

Linkedin

Facebook

Our Leadership Principles

Our Management 

Our Story

Our Services

About Redcare

Press Releases

Blog

Public Affairs

Media Downloads

Sign up

Newsroom

Patient Care

Employee Care

Planetary Care

Sustainability

Overview

Share

News

Events and Publications

Corporate Governance

Contact

Investor Relations

Our Culture

Our Departments

Life at Redcare

Jobs

FAQs

Career

No results found

About us

Careers

LinkedIn

Twitter

Redcare Pharmacy delivers strong Q3, with revenue increasing 18% driven by Rx and adjusted EBITDA margin up 1.0pp YoY to 3.4%.

Sevenum, the Netherlands, October 29, 2026. Redcare Pharmacy delivered another strong performance in the third quarter of 2026, realizing a net profit for the second consecutive quarter. Group revenue increased 18% to EUR 847 million (Q3'25: EUR 719 million) driven by strong Rx growth in Germany. Adjusted EBITDA increased 68% to EUR 29 million, corresponding to a margin of 3.4% versus 2.4% in Q3 2025. For the first nine months of 2026, Group revenue increased 19% to EUR 2.55 billion (9M'25: EUR 2.15 billion) while adjusted EBITDA reached EUR 73 million, a margin of 2.9%.

The active customer base reached 15.2 million at the end of September, an increase of 1.5 million or 11% year over year and 0.5 million versus Q2. Customer satisfaction remained high with an overall Net Promoter Score (NPS) of 76 and an e-Rx NPS of 78.

Peter Schmid von Linstow, CEO of Redcare Pharmacy, comments: „Our Rx business in Germany has performed strongly in Q3 and we are especially happy about having increased our active customer base by 123K customers in Q3, nearly doubling the 65K increase in Q2. Q3 was also a significant step forward in terms of profitability in DACH where we increased EBITDA margin by 1.2pp year over year to 4.2%. We will continue to optimize our marketing mix and increase operational leverage to translate scale into profitability across all segments.”

Strong growth in Rx and robust growth in non-Rx.

Group non-Rx revenue increased 9% year over year to EUR 489 million (Q3'25: EUR 447 million). In DACH, non-Rx revenue grew 8% to EUR 340 million, compared to EUR 315 million in Q3 2025.

Rx revenue increased 31% to EUR 358 million (Q3'25: EUR 272 million) driven by Germany where Rx revenue grew 56% to EUR 197 million. In Switzerland (MediService), Rx revenue grew 10% to EUR 161 million.

Total DACH revenue increased 19% to EUR 697 million (Q3'25: EUR 587 million) while total International revenue grew 13% to EUR 149 million (Q3'25: EUR 132 million).

Significant improvement of profitability.

Gross profit increased to EUR 185 million in Q3'26 (Q3'25: EUR 159 million). The gross profit margin was 21.8%, compared with 22.1% in Q3'25. The year-over-year decline of 0.3pp was considerably smaller than the 1.7pp point decline in Q2.

Adjusted selling and distribution expenses, which amounted to EUR 132 million, accounted for 16% of revenue, improving from 17% in Q3’25. This reduction is driven by lower marketing spend and lower cost per order. Adjusted administrative expenses, which totaled EUR 24 million, accounted for 3% of revenue, in line with Q3’25.

As a result, the adjusted EBITDA increased 68% to EUR 29 million, compared to EUR 17 million in the prior-year quarter. The adjusted EBITDA margin improved by 1.0pp to 3.4%. For the first nine months of 2026, Group adjusted EBITDA reached EUR 73 million, a margin of 2.9%. In Q3, net income was positive at EUR 1 million and free cash flow was EUR 15 million.

DACH contributed an adjusted EBITDA of EUR 29 million, up from EUR 18 million in Q3'25, with a margin of 4.2% after 3.0% last year. The International segment's adjusted EBITDA was flat year over year at EUR -1 million, corresponding to a margin of -0.4%.

Redcare Pharmacy confirms its upgraded guidance for the full year 2026:

Irina Zhurba (Director, Investor Relations)

Sven Schirmer (Director, Corporate Communications)

Originally founded in 2001, Redcare Pharmacy N.V., with EUR 2.9B in revenues in 2025, is the leading online pharmacy in Europe and active in seven countries (Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland). Headquartered in the Netherlands, Redcare Pharmacy offers its over 15 million active customers more than 500,000 different healthcare-related products. Besides OTC drugs, nutritional supplements, beauty and personal care products, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands, operating as a true one-stop pharmacy. As the pharmacy of the future, Redcare stands for comprehensive pharmaceutical services for its customers – with pharmaceutical safety always being the top priority.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange, Prime Standard, since 2016 and is part of the SDAX.

Redcare Pharmacy delivered another strong performance in the third quarter of 2026, realizing a net profit for the second consecutive quarter. 

Redcare Pharmacy delivers strong Q3, with revenue increasing 18% driven by Rx and adjusted EBITDA margin up 1.0pp YoY